Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-NET: NETrin antibodies with azacitidine + venetoclax in refractory acute myeloid leukemia
2023-503408-10-00Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by Centre Léon Bérard. Started Aug 2023; status: completed.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-503408-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503408-10-00.